Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PAREXEL and NTUH Enter Partnership

Published: Friday, November 30, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.

PAREXEL International Corporation and the National Taiwan University Hospital (NTUH) have announced that they have established an alliance.

Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.

“Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of Phase I-IV clinical trials in a rapidly growing market,” said Joe Avellone, M.D., Corporate Senior Vice President, Clinical Research Services, PAREXEL International.

Avellone continued, “The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients’ programs in the region and help them to compete more effectively in the global marketplace.”

“We are delighted to collaborate with PAREXEL, a world-leading biopharmaceutical services provider” said Ming-Fong Chen, M.D., Ph.D., Superintendent at National Taiwan University Hospital.

Chen continued, “PAREXEL has a wealth of experience in both local and global clinical development programs. This partnership will bring opportunities for both PAREXEL and NTUH to leverage our combined expertise in order to accelerate clinical development programs in Taiwan and meet patients’ need for more effective treatments.”

The alliance will drive greater efficiency for biopharmaceutical sponsors worldwide.

As a center of excellence for clinical trials in Taiwan and the Asia-Pacific region, the National Taiwan University Hospital is ideally positioned to support PAREXEL in delivering a superior clinical development service to local and global biopharmaceutical companies.

The combined experience and development expertise of the two organizations will help to create innovative solutions for biopharmaceutical companies looking to develop or market their products within this important region.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PAREXEL to Acquire Health Advances
Acquisition will strengthen PAREXEL’s leadership in strategic consulting services.
Thursday, January 21, 2016
PAREXEL Expands Market Access and Clinical Evidence Services
Greater emphasis on medical affairs, commercialization and lifecycle management for biopharmaceutical products.
Tuesday, November 24, 2015
PAREXEL Launches Next Generation Analytics Capabilities within Perceptive MyTrials® Platform
Enhancements offer clients cross-study oversight through mobile-enabled reporting and analysis.
Saturday, August 08, 2015
PAREXEL Announces Acquisition of HERON Group LTD
Company has acquired all of the outstanding equity securities of the HERON.
Tuesday, May 07, 2013
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!